中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (11): 797-800.doi: 10.12144/zgmfskin202511797

• 临床研究 • 上一篇    下一篇

雷公藤多苷联合度普利尤单抗治疗特应性皮炎疗效评价

陈玉宝1,张涛2,尹冬1,任尚立1   

  1. 1张家口学院附属人民医院（张家口市第一医院）皮肤科，河北张家口，075000; 2中国医学科学院北京协和医院皮肤科，北京，100032
  • 出版日期:2025-11-15 发布日期:2025-11-11

Efficacy of tripterygium glycosides wilfordii combined with dupilumab in the treatment of atopic dermatitis

CHEN Yubao1, ZHANG Tao2, YIN Dong1, REN Shangli1   

  1. 1 Department of Dermatology, Zhangjiakou University Affiliated People's Hospital （Zhangjiakou First Hospital）, Zhangjiakou 075000, China; 2 Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100032, China
  • Online:2025-11-15 Published:2025-11-11

PDF (PC)

22

摘要： 目的：分析雷公藤多苷联合度普利尤单抗治疗特应性皮炎（atopic dermatitis, AD）的临床疗效。方法：分析2023年2月至2024年2月于我院治疗的AD患者。对照组为基础治疗加度普利尤单抗，雷公藤组在对照组基础上加雷公藤多苷治疗。比较两组治疗有效率,以EASI评分下降≥50%为治疗有效。结果：共治疗患者88例，每组44例，对照组有3例、雷公藤组有4例脱落。雷公藤组有效率90%,高于对照组（70.73%）(P＜0.05)。两组不良反应发生率分别为17.08%和22.50%，差异无统计学意义（P＞0.05）。两组治疗4、8和12周后EASI评分、Itch-NRS评分、IGA评分和DLQI评分均低于治疗前，且雷公藤组下降更明显，差异均有统计学意义（均P＜0.05）。结论：雷公藤多苷联合度普利尤单抗疗效优于单用度普利尤单抗，无严重不良反应。

关键词: 雷公藤多苷, 度普利尤单抗, 特应性皮炎, 治疗反应性

Abstract: Objective: To analyze the clinical efficacy of tripterygium glycosides combined with dupilumab in the treatment of atopic dermatitis (AD). Methods: AD patients treated in our hospital from February 2023 to February 2024 were included in the analysis. The control group received basic treatment plus dupilumab, while the tripterygium group was given tripterygium glycosides on the basis of the treatment regimen for the control group. The treatment response rate was compared between the two groups, with a ≥50% reduction in EASI score defined as a therapeutic response. Results: A total of 88 patients were treated, with 44 cases in each group. Three cases were lost to follow-up in the control group and 4 cases in the tripterygium group. The response rate of the tripterygium group was 90%, which was significantly higher than that of the control group (70.73%) (P＜0.05). The incidence of adverse reactions was 17.08% in the control group and 22.50% in the tripterygium group, with no statistically significant difference between the two groups (P＞0.05). After 4, 8, and 12 weeks of treatment, the EASI score, Itch-NRS score, IGA score, and DLQI score in both groups were lower than those before treatment; the reduction in the tripterygium group was more significant, and all differences were statistically significant (Ps＜0.05). Conclusions: The efficacy of tripterygium glycosides combined with dupilumab is superior to that of dupilumab alone in the treatment of AD, with no serious adverse reactions.

Key words: tripterygium glycosides wilfordii, dupilumab, atopic dermatitis, therapeutic responsiveness